Craft

Alzamend Neuro

Stock Price

$1.6

2024-10-29

Market Capitalization

$7.2 M

2024-10-29

Alzamend Neuro Summary

Company Summary

Overview
Alzamend Neuro is a biopharmaceutical company developing treatments for neurodegenerative diseases and psychiatric disorders. It offers mutant-peptide immunotherapeutic AL002, for use as a treatment or vaccine, and a lithium-based ionic cocrystal therapy AL001, that reduces or eliminates the symptoms of agitation and other endpoints for mild to moderate stage patients diagnosed with Alzheimer’s disease.
Type
Public
Status
Active
Founded
2016
HQ
Tampa, FL, US | view all locations
Website
https://alzamend.com/
Cybersecurity rating
Sectors

Key People

  • Stephan Jackman

    Stephan Jackman, Chief Executive Officer and Director

  • Ken Cragun

    Ken Cragun, Senior Vice President of Finance

  • Henry C.W. Nisser

    Henry C.W. Nisser, Executive Vice President, General Counsel and Director

  • William B. Horne

    William B. Horne, Chairman

    LocationsView all

    2 locations detected

    • Tampa, FL HQ

      United States

      3802 Spectrum Blvd #112c

    • Newport Beach, CA

      United States

      201 Shipyard Way ste e

    Alzamend Neuro Financials

    Summary Financials

    Net income (Q3, 2026)
    ($2.2M)
    Cash (Q3, 2026)
    $2.7M
    EBIT (Q3, 2026)
    ($2.2M)

    Footer menu